Combination treatment with PD-1/PD-L1 and CTLA-4 blockades might provide greater anti-tumor activity than single drugs as targeting both pathways may have synergistic effects (Hellmann et al., 2017; Wei et al., 2017). The gene discussed is CD274; the disease is neoplasm.